

**Shionogi to Present New Data on S-033188,  
a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza,  
at the 6th European Scientific Working Group in Influenza Conference**

**Osaka, Japan, September 8, 2017** - Shionogi & Co., Ltd. today announced it will be presenting new data on S-033188, an investigational cap-dependent endonuclease inhibitor targeting influenza at this year's European Scientific Working Group in Influenza Conference (ESWI), held in Riga, Latvia, September 10 – 13, 2017.

Highlights of S-033188 presentations will showcase both clinical and non-clinical data (e.g., Phase 3 study in influenza patients (CAPSTONE-1)).

Below is an overview of the oral and poster presentations featuring S-033188 at ESWI 2017:

<b>Presentation</b>	<b>Presentation Information</b>
Cap-Dependent Endonuclease Inhibitor S-033188 for the Treatment of Influenza in Otherwise Healthy Adolescents and Adults with Seasonal Influenza	Oral Presentation Wednesday, September 13, 2017 Presenter: Frederick Hayden
Effects of S-033188, a cap-dependent endonuclease inhibitor, on influenza symptoms and viral titer: Results from a phase 2, randomized, double-blind, placebo-controlled study in otherwise healthy adults with seasonal influenza	Poster Presentation Presenter: Keiko Kawaguchi
Inhibitory Effect of S-033188, a novel inhibitor of influenza virus cap-dependent endonuclease, against avian influenza A/H7N9 virus in vitro and in vivo.	Poster Presentation Presenter: Keiichi Taniguchi
S-033188, a novel inhibitor of influenza virus cap-dependent endonuclease, leads to rapid and profound viral load reduction in immunocompromised mice model	Poster Presentation Presenter: Yoshinori Ando

Shionogi & Co., Ltd. will be presenting further data on CAPSTONE-1 study results at this year's Infectious Disease Week 2017, held in San Diego, San Francisco, October 4 – 8, 2017.

***Forward Looking Statement***

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

**Contacts:**

Corporate Communications, Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596

###